DIGITAL-ENVOY
14.7.2020 13:02:08 CEST | Business Wire | Press release
Digital Envoy, the inventor of IP intelligence, today announced that Jerrod Stoller has been appointed as its new President. Current President and CEO Bill Calpin has stepped back from his role and has been named Chairman of the Board. Co-founder and Executive Vice President Rob Friedman assumes a dual role with the addition of the Vice-Chairman title.
Stoller will assume day-to-day leadership of Digital Envoy, overseeing operations for all three business units: Digital Element , Digital Resolve and Gathr Lab . His focus will be driving product innovation and market strategy across all three business units to align all offerings even closer with the needs of current customers and the marketplaces at large.
“The Digital Envoy team has accomplished great things since our start in 1999, and I am extremely proud of the growth and success our teams have achieved during that time,” said Calpin. “Our accomplishments have always been reliant on the entire team and the common goal of making Digital Envoy bigger and better. As Jerrod joins the team, all of us will continue to play key roles in helping our company maximise its potential. Based on his past experiences and successes, it’s easy to understand the enthusiasm our entire team has for Jerrod joining and leading our company into the future.”
Before joining Digital Envoy, Stoller was CEO of eVestment where he had directed the sales, marketing, client success and business development activities of the organisation globally for almost 10 years. He took on the CEO role 18 months ago, while retaining his other duties. Before joining eVestment, Stoller was the Regional Manager of RSA, the Security Division of EMC, where he directed company performance into triple-digit growth. Prior to RSA, he held leadership roles with Datalex Transportation Enterprise Software, Siemens Business Services, TransQuest Business Consulting and NCR. Stoller holds a bachelor’s degree in finance from Purdue University.
“I am thrilled to assume this new role and incredibly excited about what we can accomplish together for the future,” said Stoller. “There is tremendous opportunity ahead for Digital Envoy. I look forward to continuing to support our clients at the highest levels as well as innovating new market and product strategies within our industry niches to solve real-world problems.”
All changes are effective immediately.
“As Digital Envoy has continued to grow, we felt the need to expand the team to help focus on both the operational and strategic needs of the company,” said Friedman. “For Bill and I, our new roles provide opportunities to continue to stay engaged in the business while also providing us more time to address some of the longer-term opportunities and partnerships available to us as the markets continue to change.”
About Digital Envoy
Launched in 1999, Digital Envoy introduced the concept of privacy-sensitive IP-based geolocation and IP intelligence, allowing businesses—from ad networks to publishers to websites to retailers and more—to harness the power of location and new intelligence about connected users for a multitude of mission-critical applications. Taking more of a background role, in 2005 Digital Envoy introduced two divisions to help best address the unique needs of its diverse audience segments and business applications: Digital Element, which was created to continue the legacy of providing global geolocation data and services that bring anytime, anywhere relevance and context to online and mobile initiatives; and Digital Resolve, which was launched to deliver solutions that proactively secure online accounts, information, transactions and interactions from login to logout. In 2019, Digital Envoy launched Gathr Lab to further expand on its two decades of location data expertise and provide anonymous, custom audience insights and segments at scale, across all devices. By helping clients to reach, understand and amplify their best audiences, Gathr Lab is leading change by committing to data anonymity and refreshing transparency rooted in location-based data science. Visit www.digitalenvoy.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom